Recently, we treated a 10-year-old boy with the diagnosis of severe aplastic anemia with total body irradiation (TBI) as part of an allogeneic sibling-matched bone marrow transplant. This was the second allogeneic sibling-matched transplant for this patient. TBI was used as part of the preparative regimen for the second transplant after the child suffered graft rejection after the first transplant.
Our prescribed radiation dose was 4 Gy (two fractions of 2 Gy each) delivered with 23 MV photons. With this relatively low dose and the absence of concern about the testicles as a sanctuary site, the possibility of testicular shielding to preserve fertility was discussed. To our knowledge, the concept and, more importantly, the technical aspects of testicular shielding in the setting of TBI have not been reported previously. We, therefore, undertook dosimetric measurements to determine the best technique to provide testicular shielding in a TBI patient.
Human spermatogenesis is very sensitive to radiation. Permanent sterility can result after fractionated doses in the range of 1.4-3 Gy.
1,2 Accordingly, we evaluated various types of testicular shielding with the goal of lowering scrotal dose to less than 1 Gy in an attempt to preserve fertility.
The concept of testicular shielding when using diagnostic imaging or pelvic external beam radiotherapy is well established. Hernandez et al.
3 described the simple technique of placing a lead disc on top of the incubator when imaging neonates. Positioning the lead to shield the gonads was performed by using the collimator light and placing the shadow over the testicles. Several authors have described various testicular shields to limit scatter radiation to the testicles from near-field external beam radiation to the abdomen or pelvis. Fraass et al. 4 described the use of a clamshell scrotal shield when delivering near-field external beam treatments, with a dose reduction of at least 5% when the field-edge is 1.5 cm from the scrotum with greater decreases as the distance from the field-edge increases. Kubo and Shipley 5 describe retroperitoneal radiotherapy in which the gonads are shielded using (a) standard beam shaping at the collimator (b) additional 10 cm thick lead block above the scrotum (outside the primary beam) and (c) a clamshell resulting in significant dose reduction to the testicles.
Our testicular shielding problem differs from the above literature in that our patient is undergoing TBI where the testicles remain directly in the radiation beam. Our first thought was to use the standard external beam clamshell shielding. However, because of the direct interaction of the TBI photons with the lead of the clamshell, we became concerned about scatter radiation affecting dose to the scrotum. Therefore, we carried out dosimetric measurements with various testicular shields.
We evaluated the standard two-sided (1.3 cm thick per side) lead clamshell. A micro-ionization chamber was utilized to take measurements within the clamshell. We also evaluated single lead shields of thickness 1.3, 2.4 and 5 cm. For the single lead shields, measurements were carried out using a parallel plate chamber. TBI was delivered with both 6 and 23 MV photons at an extended distance with a 1.7 g/cm 2 beam spoiler. We established that with the use of a standard two-sided clamshell, dose to the scrotum was actually increased by a factor of 1.15 with 23 MV photons. This dose increase at shallow depths is from electrons and low-energy photons generated from the megavoltage photons on the inside wall of the gonadal shield and subsequent scatter inside the shield. Adding bolus of 0.5 or 2.5 cm to the inside of the clamshell to absorb scattered electrons and low-energy Xrays provided only a modest reduction in dose (transmission of 0.90 and 0.68 Â , respectively).
Using single lead shields resulted in significant lowering of the dose to the scrotum. With a TBI prescription dose of 4 Gy, resultant radiation transmission and scrotal dose by lead thickness and photon energy are shown in Table 1 .
From our dosimetric studies, we have concluded the following:
1. Meaningful testicular shielding (doseso1 Gy) can be achieved using a single 5 cm lead shield. This should result in preserved male fertility after low-dose TBI in patients where testicular sanctuary status is not a concern, as was the case with our patient with aplastic anemia. 
